Pancreatic Cancer

Oncology·MeSH: Pancreatic Neoplasms

Prevalence

8.0 / 100K

Incidence

13.1 / 100K/yr

101 drugs in development·55 companies·89 clinical trials

Drug Pipeline by Phase

Approved(1)
DrugCompany
ABRAXANEImmunityBio, Inc. (IBRX)
Phase 3(21)
DrugCompany
atebimetinibImmuneering Corp (IMRX)
bcg+n-803. )ImmunityBio, Inc. (IBRX)
ChemotherapyENANTA PHARMACEUTICALS INC (ENTA)
fludarabineFilana Therapeutics Inc. (FLNA)
FOLFIRINOXIGM Biosciences, Inc. (IGMS)
FOLFIRINOX chemotherapyMerus N.V. (MRUS)
glufosfamideBullfrog AI Holdings Inc. (BFRG)
gnpImmuneering Corp (IMRX)
iagRenovoRx, Inc. (RNXT)
Investigator's Choice of ChemotherapyENANTA PHARMACEUTICALS INC (ENTA)
ivospeminPANBELA THERAPEUTICS, INC. (SNBP)
leucovorinREVOLUTION MEDICINES, INC. (RVMD)
LeucovorinTango Therapeutics, Inc. (TNGX)
mgnpImmuneering Corp (IMRX)
Platinum chemotherapyENANTA PHARMACEUTICALS INC (ENTA)
SetidegrasibTango Therapeutics, Inc. (TNGX)
SetidegrasibMerus N.V. (MRUS)
Sintilimab injectionKYNTRA BIO INC. (KYNB)
tak-500Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-500TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
zoldonrasibREVOLUTION MEDICINES, INC. (RVMD)
Phase 2(22)
DrugCompany
ABV-1703ABVC BIOPHARMA, INC. (ABVC)
ampligenAIM ImmunoTech Inc. (AIM)
Ampligen (rintatolimod)AIM ImmunoTech Inc. (AIM)
Anti-EGFRMerus N.V. (MRUS)
Anti-PD-1 monoclonal antibodyMerus N.V. (MRUS)
cyt-0851Cyteir Therapeutics, Inc. (CYT)
FOLFIRIMerus N.V. (MRUS)
FolfirinoxMerus N.V. (MRUS)
FolfirinoxKYNTRA BIO INC. (KYNB)
folfirinox aloneSalspera, Inc. (TKVA)
LeucovorinImmunityBio, Inc. (IBRX)
mFOLFIRINOXMerus N.V. (MRUS)
mFOLFIRINOXKYNTRA BIO INC. (KYNB)
mFOLFIRINOX infusionMerus N.V. (MRUS)
mFOLFIRINOX Treatment RegimenKYNTRA BIO INC. (KYNB)
nal-IRI,5-fu,LV, benmelstobart, anlotinibMerus N.V. (MRUS)
regorafenibIncyte Corp. (INCY)
RintatolimodAIM ImmunoTech Inc. (AIM)
rucosopasem manganeseGalera Therapeutics, Inc. (GRTX)
salmonella-il2Salspera, Inc. (TKVA)
sig12d-loderSilexion Therapeutics Corp (SLXN)
TripegfilgrastimKYNTRA BIO INC. (KYNB)
Phase 1(26)
DrugCompany
AB680Arcus Biosciences, Inc. (RCUS)
ADCT-601ADC Therapeutics SA (ADCT)
APX005MArcus Biosciences, Inc. (RCUS)
APX005MIGM Biosciences, Inc. (IGMS)
BNT321 0.5 mg/kgBioNTech SE (BNTX)
BNT321 DL 2BioNTech SE (BNTX)
BNT321 RP2DBioNTech SE (BNTX)
BP1001-ABIO-PATH HOLDINGS, INC. (BPTH)
CT-1119Carisma Therapeutics Inc. (CARM)
FOLFIRIArcus Biosciences, Inc. (RCUS)
fpa150FIVE PRIME THERAPEUTICS, INC. (FPRX)
individualized anti-tumor new antigen iNeo-Vac-R01 injectionKYNTRA BIO INC. (KYNB)
mFOLFIRINOXBioNTech SE (BNTX)
modified folfirinoxAMGEN INC (AMGN)
mvt-5873MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX)
N-803ImmunityBio, Inc. (IBRX)
nelitolimodTriSalus Life Sciences Inc. (TLSI)
PD-L1 t-haNKImmunityBio, Inc. (IBRX)
pritumumabNascent Biotech Inc. (NBIO)
qn-302AIxCrypto Holdings, Inc. (AIXC)
rmc-6236AMGEN INC (AMGN)
sotevtamabImmunityBio, Inc. (IBRX)
srf617Surface Oncology, Inc. (SURF)
sy-5609Syros Pharmaceuticals, Inc. (SYRS)
TROP2-CAR-NKFilana Therapeutics Inc. (FLNA)
zabadinostatImmunityBio, Inc. (IBRX)

Compare drugs

ABRAXANE vs atebimetinibABRAXANE vs bcg+n-803. )ABRAXANE vs Chemotherapy

Frequently asked questions

How many drugs are in development for Pancreatic Cancer?

BioSniper tracks 101 drugs in development for Pancreatic Cancer across 55 companies.

How many clinical trials target Pancreatic Cancer?

There are 89 clinical trials targeting Pancreatic Cancer tracked by BioSniper.

What is the prevalence of Pancreatic Cancer?

The estimated prevalence of Pancreatic Cancer is approximately 8.0 per 100,000 population.

Deep-dive into Pancreatic Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis